Damian Doherty

2 weeks ago | insideprecisionmedicine.com | Damian Doherty |Julianna LeMieux |Corinna Singleman

Damian Doherty, Editor in Chief at IPM, and Julianna LeMieux, PhD, Deputy Editor in Chief at Genetic Engineering and Biotechnology News, shared their initial experiences at the start of the American Association for Cancer Research (AACR) meeting. They are covering everything they can from talks to the expo hall, and news from the press room. Here, they take a moment to chat about the first few days at the meeting with a focus on the opening plenary session.

Feb 10, 2025 | insideprecisionmedicine.com | Damian Doherty |Kathy Vuksanaj

Inside Precision Medicine editor in chief Damian Doherty recently sat down with two leading experts, Thomas Sakmar, MD, of Rockefeller University, a pioneer in G protein–coupled receptor (GPCR) research and chemical biology, and Jochen Schwenk, PhD, of SciLifeLab in Sweden and the Human Protein Atlas, a pioneer in proteomics and multiplexed immunoassays.

Dec 4, 2024 | insideprecisionmedicine.com | Damian Doherty |Kathy Vuksanaj

Kathy Dong, PharmD, is the president and CEO of Electra Therapeutics, a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer. The company’s lead drug candidate, ELA026, is a first-in-class monoclonal antibody that represents the new generation of drugs for immunology and inflammation—now referred to as I&I drugs—that selectively target disease-causing pathways of the immune system with precision.

Aug 13, 2024 | insideprecisionmedicine.com | Damian Doherty

Most patients with newly diagnosed melanoma present with early-stage disease. Although surgical resection can lead to a cure for most of these patients, a high-risk subset faces the risk of relapse and death from melanoma. However, this subset may benefit from approved systemic adjuvant therapy. The question is, how do we identify these patients?

Apr 1, 2024 | insideprecisionmedicine.com | Damian Doherty

Maria Fardis, PhD, is the chief executive officer of Lassen Therapeutics, a clinical-stage company advancing first-in-class antibodies as potential treatments for fibro-inflammatory disorders and cancer. The company’s lead candidate, LASN01, targets the interleukin receptor (IL-11R) and is currently being evaluated in clinical trials for the treatment of thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).